Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target hoisted by Evercore ISI from $33.00 to $45.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...

We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20 ...